ImmVirX extends Research Services Agreement with University of Newcastle & HMRI through to 2024
Melbourne, Australia 6 December 2021 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic viral immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, today announced the option to extend its relationship with the University of Newcastle through to December 2024. Under the ongoing Research Services […]
